Rank;Global Rank;Institution;Country;Sector
1;103;Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique;FRA;Companies
2;166;GlaxoSmithKline, United Kingdom;GBR;Companies
3;185;Sanofi, France;FRA;Companies
4;187;Sanofi, United States;USA;Companies
5;190;GlaxoSmithKline, United States;USA;Companies
6;209;Bristol-Myers Squibb Company, United States;USA;Companies
7;213;Hoffmann-La Roche Ltd, United States;USA;Companies
8;226;Genentech Inc;USA;Companies
9;228;AstraZeneca, Sweden;SWE;Companies
10;239;AstraZeneca, United Kingdom;GBR;Companies
11;242;Regeneron Pharmaceuticals Inc;USA;Companies
12;243;Novartis Institutes for Biomedical Research, United States;USA;Companies
13;244;Merck & Co Inc, United States;USA;Companies
14;294;AstraZeneca, United States;USA;Companies
15;316;Boehringer Ingelheim GmbH Germany;DEU;Companies
16;336;Novartis, Switzerland;CHE;Companies
17;377;Eli Lilly and Company, United States;USA;Companies
18;385;Janssen Biotech Inc;USA;Companies
19;551;Ormat Technologies, United States;USA;Companies
20;582;Boehringer Ingelheim, USA;USA;Companies
21;617;Bosch, Germany;DEU;Companies
22;683;Novartis Pharmaceuticals, United States;USA;Companies